Hematologic Oncology

Jeffery Auletta, MD, discusses the impact of post-transplant cyclophosphamide in hematologic malignancies.

Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.

Stephanie Lee, MD, MPH, discusses 3-year follow-up data from the phase 3 ROCKstar Study of belumosudil in cGVHD.

Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.

Concomitant azoles did not negatively affect efficacy with ruxolitinib or best available therapy in patients with acute graft-versus-host disease.

Ruxolitinib and belumosudil demonstrated a beneficial ORR, indicating synergistic effects in targeting multiple inflammatory pathways in chronic GVHD.

A cream formulation of ruxolitinib was deemed safe and effective compared with placebo in patients with cutaneous graft-versus-host disease.

Speculation on anticipated innovations in allo-HSCT and cellular therapy technologies in the future.

The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.

Early data seen with acalabrutinib plus axi-cel indicate the combination’s feasibility as bridging therapy in relapsed/refractory B-cell lymphoma.

The FDA has granted IO-202 an orphan drug designation for patients with chronic myelomonocytic leukemia.

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz share their predictions for the next 3 to 5 years in chronic GVHD management. The panel anticipates advancements in earlier treatment, potential elimination of frontline corticosteroids, and a shift towards preventive strategies and personalized medicine.

The panel reviews axatilimab, an emerging agent for chronic GVHD under clinical studies. The experts explore findings from the Agave-201 study, highlighting potential challenges of intravenous administration and axatilimab’s unique mechanisms.

The FDA granted an orphan drug designation to ocifisertib for use as a potential therapeutic option in patients with acute myeloid leukemia.

Clinical insights on selecting appropriate erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.

Carrie L. Kitko, MD, and Sagar S. Patel, MD, discuss recent treatment developments and ongoing unmet needs in the graft-vs-host treatment paradigm.

Criteria for identifying patients with MDS most likely to benefit from transplant and choosing the optimal donor source and conditioning regimen on a case-by-case basis.

Experts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.

Safety and toxicity data from a clinical trial investigating a novel, precision-engineered allo-HSCT conditioning regimen for older patients with high-risk blood cancers.

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss a complex chronic GVHD case post-allogeneic transplant. The panel explores third-line options, including belumosudil, ibrutinib, photopheresis, and clinical trials, emphasizing shared decision-making and the need for well-designed trials in guiding treatment decisions.

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz review a clinical scenario of chronic GVHD post-allogeneic transplant. They explore treatment options and emphasize shared decision-making, considering patient preferences and therapeutic benefits.

Mikkael A. Sekeres, MD, MS, highlights recent approvals and emerging therapeutics in hematologic malignancies discussed by his colleagues.

The expert panel provides comprehensive insights on another patient case, a 77-year-old with MDS who presented with symptomatic anemia.

Continuing their discussion on the first patient profile, the expert panel focuses on the second-line treatment of patients with lower-risk MDS and symptomatic anemia.